查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1454070

自動注射器市場至2030年的預測：按類型、治療、給藥途徑、技術、最終用戶和地區的全球分析

Autoinjectors Market Forecasts to 2030 - Global Analysis By Type (Reusable, Disposable, Customized, Prefilled and Other Types), Therapy, Route of Administration, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球自動注射器市場規模將達到 1,111 億美元，預計到2030年將達到 2,646 億美元，預測期內年複合成長率為 13.2%。

自動注射器是醫療設備，設計用於在緊急情況下注射單一劑量的特定藥物，例如嚴重過敏反應或其他醫療緊急情況。該設備結構緊湊、攜帶且易於使用，使個人能夠快速、輕鬆地自行給藥。這些設備通常用於輸送治療過敏反應的腎上腺素、軍事用的神經毒劑解毒劑或治療多發性硬化症和類風濕性關節炎等慢性疾病的藥物。在急診醫學領域，在時間緊迫的情況下快速提供救命藥物方面發揮著重要作用。

根據美國國家健康調查（NHIS），近 52%的美國成年人被診斷出患有至少一種慢性病，包括氣喘、糖尿病和高血壓。

慢性病增加

類風濕性關節炎、多發性硬化症和糖尿病等疾病在世界各地變得越來越普遍，增加了對方便且高效的藥物輸送系統的需求。自動注射器為患者提供了一個易於使用的自我給藥解決方案，並有助於其在慢性病管理中的日益普及。這一趨勢凸顯了醫療保健領域創新和可近性的重要性，以滿足慢性疾病患者不斷變化的需求。

嚴格的監管要求

滿足嚴格的監管要求是在該市場營運的公司面臨的主要挑戰。這些要求包括安全性、功效、品管和製造標準等各個方面。在產品的整個生命週期中，需要進行廣泛的測試、記錄並遵守嚴格的準則，以確保符合監管機構制定的法規。違規可能導致產品核可延遲、代價高昂的召回以及公司聲譽受損。

過敏反應和嚴重過敏反應迅速增加

自動注射器市場的過敏反應和嚴重過敏反應顯著增加。該成長凸顯了對可靠、高效的緊急治療提供機制的迫切需求。在這些緊急情況下，自動注射器在快速、準確地施用救生藥物方面發揮關鍵作用。隨著意識的增強和越來越多的人需要使用此類設備，市場對改進技術和創新的需求不斷成長，以滿足這種緊迫的醫療需求。

自動注射器高成本

自動注射器的高價格仍然是市場的主要挑戰。這些設備對於治療嚴重過敏反應的腎上腺素等藥物非常重要，但它們的價格往往過高，給患者和醫療保健系統帶來了經濟負擔。儘管有潛在的挽救生命的作用，但高價格限制了可及性，並導致人們對公平醫療保健的擔憂。解決這一問題的努力包括倡導學名藥替代品和提高定價透明度以減輕患者的經濟負擔。

COVID-19 的影響：

COVID-19 大流行對自動注射器市場產生了重大影響。最初，供應鏈中斷導致製造和分銷短缺和延誤。然而，隨著疫情的發展，由於人們越來越關注自我給藥和遠距醫療的需求，對自動注射器的需求激增。因此，在疫情的挑戰下，自動注射器市場因慢性病增加和對家庭醫療保健解決方案的偏好等因素而擴大。

拋棄式區隔在預測期內將是最大的

預計拋棄式區隔在預測期內將是最大的。這些設備易於使用，降低針刺傷害的風險，並提高患者的依從性和安全性。慢性病盛行率上升和生技藥品使用範圍擴大等因素推動市場擴張。此外，技術進步和產品創新也促進了市場的成長。

預計糖尿病產業在預測期內年複合成長率最高

由於全球糖尿病盛行率不斷上升以及自我管理技術的進步，預計糖尿病產業在預測期內將出現最高的年複合成長率。自動注射器提供胰島素注射的便利性和準確性，並提高患者的依從性。此外，目的是提高設備功效和患者體驗的研發投資預計將推動主要產業參與者之間的創新和競爭，維持市場勢頭。

佔有率最大的地區

由於糖尿病和類風濕性關節炎等慢性病的盛行率不斷上升，預計北美在預測期內將佔據最大的市場佔有率。此外，自我給藥設備的日益普及和給藥系統的技術進步推動市場擴張。此外，有利的政府舉措和償付政策支持全部區域自動注射器的普及並促進市場開拓。

年複合成長率最高的地區：

預計亞太地區在預測期內將維持最高的年複合成長率。該地區糖尿病、類風濕性關節炎、多發性硬化症和過敏反應等慢性病的盛行率日益增加。亞太地區各國監管機構越來越注重確保包括自動注射器在內的醫療設備的安全性和有效性。每個國家的人口老化推動對自動注射器的需求，因為老年人經常患有慢性疾病並需要定期用藥。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球自動注射器市場：依類型

  • 可重複使用
  • 一次性
  • 客製化
  • 預填充
  • 其他類型

第6章 全球自動注射器市場：依處理方式

  • 腫瘤學
  • 氣喘
  • 類風濕性關節炎
  • 多發性硬化症
  • 過敏反應
  • 荷爾蒙療法
  • 糖尿病
  • 偏頭痛
  • 其他治療

第7章 全球自動注射器市場：依給藥途徑

  • 肌肉注射
  • 皮下

第8章 全球自動注射器市場：依技術分類

  • 手動
  • 彈簧式
  • 電池供電
  • 其他技術

第9章 全球自動注射器市場：依最終用戶分類

  • 醫院和診所
  • 居家照護環境
  • 門診就診環境
  • 其他最終用戶

第10章 全球自動注射器市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Pfizer, Inc
  • Eli Lilly and Company
  • AbbVie Inc
  • GlaxoSmithKline plc
  • Mylan NV
  • Johnson & Johnson
  • Sanofi
  • Amgen Inc
  • Merck KGaA
  • Antares Pharma, Inc.
  • Becton, Dickinson, and Company
  • Janssen Global Services, LLC
  • Teva Pharmaceutical
  • Novartis AG
  • Bayer AG
  • SHL Medical
  • Solteam Medical
  • Stevanato Group
  • Boehringer Ingelheim International GmbH
Product Code: SMRC25622

According to Stratistics MRC, the Global Autoinjectors Market is accounted for $111.1 billion in 2023 and is expected to reach $264.6 billion by 2030 growing at a CAGR of 13.2% during the forecast period. Autoinjectors are medical devices designed to deliver a single dose of a particular medication, typically in emergency situations such as severe allergic reactions (anaphylaxis) or other medical emergencies. They are compact, portable, and user-friendly devices that allow individuals to self-administer medication quickly and easily. These devices are commonly used for delivering medications such as epinephrine for allergic reactions, nerve agents' antidotes for military personnel, or medications for certain chronic conditions like multiple sclerosis or rheumatoid arthritis. They play a crucial role in emergency medical care, providing rapid delivery of life-saving medication when time is of the essence.

According to the National Health Interview Survey (NHIS), nearly 52% of the adult population in the US is diagnosed with at least one chronic condition, such as asthma, diabetes, and hypertension.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

Conditions such as rheumatoid arthritis, multiple sclerosis, and diabetes are becoming more prevalent globally, driving the need for convenient and efficient drug delivery systems. Autoinjectors offer patients a user-friendly solution for self-administration of medications, contributing to their growing popularity in managing chronic conditions. This trend underscores the importance of innovation and accessibility within the healthcare sector to address the evolving needs of patients with chronic diseases.

Restraint:

Stringent regulatory requirements

Meeting stringent regulatory requirements poses significant challenges for companies operating in the market. These requirements encompass various aspects such as safety, efficacy, quality control, and manufacturing standards. Ensuring compliance with regulations set forth by regulatory bodies demands extensive testing, documentation, and adherence to strict guidelines throughout the product lifecycle. Non-compliance can lead to delays in product approval, costly recalls, and damage to the company's reputation.

Opportunity:

Surge in anaphylaxis and severe allergic reactions

There has been a notable surge in anaphylaxis and severe allergic reactions within the autoinjectors market. This increase underscores the critical need for reliable and efficient delivery mechanisms for emergency treatment. Autoinjectors play a vital role in administering life-saving medication swiftly and accurately during such emergencies. As awareness grows and more individuals require access to these devices, the market is witnessing a heightened demand for improved technologies and innovations to address these urgent medical needs.

Threat:

High cost of autoinjectors

The high cost of autoinjectors remains a significant challenge in the market. These devices, crucial for delivering medications such as epinephrine for severe allergic reactions, are often priced prohibitively high, posing financial burdens for patients and healthcare systems. Despite their lifesaving potential, the inflated prices limit accessibility, leading to concerns about equitable healthcare access. Efforts to address this issue include advocating for generic alternatives and increasing transparency in pricing to mitigate the financial strain on patients.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the autoinjectors market. Initially, disruptions in the supply chain led to shortages and delays in manufacturing and distribution. However, as the pandemic progressed, there was a surge in demand for autoinjectors due to increased focus on self-administration of medications and the need for remote healthcare. This led to a growing market for autoinjectors, driven by factors such as the rise in chronic diseases and the preference for home healthcare solutions amidst the pandemic's challenges.

The disposable segment is expected to be the largest during the forecast period

The disposable segment is expected to be the largest during the forecast period. These devices offer ease of use and reduced risk of needlestick injuries, enhancing patient compliance and safety. Factors such as increasing prevalence of chronic diseases and expanding applications of biologics drive market expansion. Additionally, advancements in technology and product innovations contribute to market growth.

The diabetes segment is expected to have the highest CAGR during the forecast period

The diabetes segment is expected to have the highest CAGR during the forecast period driven by rising prevalence of diabetes globally and advancements in self-administration technologies. Autoinjectors offer convenience and accuracy in insulin delivery, enhancing patient compliance. Moreover, increasing investments in research and development aimed at improving device efficacy and patient experience are expected to sustain market momentum, fostering innovation and competition among key industry players.

Region with largest share:

North America is projected to hold the largest market share during the forecast period attributed to the rising prevalence of chronic diseases like diabetes and rheumatoid arthritis. Additionally, the increasing adoption of self-administration devices and technological advancements in drug delivery systems are driving market expansion. Furthermore, favorable government initiatives and reimbursement policies support the widespread adoption of autoinjectors across the region, fostering market development.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The prevalence of chronic diseases such as diabetes, rheumatoid arthritis, multiple sclerosis, and anaphylaxis is increasing in the region. Regulatory bodies in various countries across the Asia Pacific region are increasingly focusing on ensuring the safety and efficacy of medical devices, including autoinjectors. The aging population in countries is driving the demand for autoinjectors as elderly individuals often require regular medication for chronic conditions.

Key players in the market

Some of the key players in Autoinjectors market include Pfizer, Inc, Eli Lilly and Company, AbbVie Inc, GlaxoSmithKline plc, Mylan N.V., Johnson & Johnson, Sanofi, Amgen Inc, Merck KGaA, Antares Pharma, Inc., Becton, Dickinson, and Company, Janssen Global Services, LLC, Teva Pharmaceutical, Novartis AG, Bayer AG, SHL Medical, Solteam Medical, Stevanato Group and Boehringer Ingelheim International GmbH.

Key Developments:

In May 2023, Boehringer Ingelheim International GmbH announced that the U.S. FDA has approved the Cyltezo Pen, an autoinjector option for Cyltezo (adalimumab), an FDA-approved interchangeable biosimilar to Humira.

In May 2023, SHL Medical and MoonLake Immunotherapeutics collaborated to develop the sonelokimab autoinjector. SHL Medical's Molly autoinjector technology will be utilized for the clinical and potential commercial supply of MoonLake's Nanobody sonelokimab.

Types Covered:

  • Reusable
  • Disposable
  • Customized
  • Prefilled
  • Other Types

Therapies Covered:

  • Oncology
  • Asthma
  • Rheumatoid arthritis
  • Multiple sclerosis
  • Anaphylaxis
  • Hormone therapy
  • Diabetes
  • Migraine
  • Other Therapies

Route of Administrations Covered:

  • Intramuscular
  • Subcutaneous

Technologies Covered:

  • Manual
  • Spring-Loaded
  • Battery-Powered
  • Other Technologies

End Users Covered:

  • Hospital & clinics
  • Homecare settings
  • Ambulatory Care Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Autoinjectors Market, By Type

  • 5.1 Introduction
  • 5.2 Reusable
  • 5.3 Disposable
  • 5.4 Customized
  • 5.5 Prefilled
  • 5.6 Other Types

6 Global Autoinjectors Market, By Therapy

  • 6.1 Introduction
  • 6.2 Oncology
  • 6.3 Asthma
  • 6.4 Rheumatoid arthritis
  • 6.5 Multiple sclerosis
  • 6.6 Anaphylaxis
  • 6.7 Hormone therapy
  • 6.8 Diabetes
  • 6.9 Migraine
  • 6.10 Other Therapies

7 Global Autoinjectors Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intramuscular
  • 7.3 Subcutaneous

8 Global Autoinjectors Market, By Technology

  • 8.1 Introduction
  • 8.2 Manual
  • 8.3 Spring-Loaded
  • 8.4 Battery-Powered
  • 8.5 Other Technologies

9 Global Autoinjectors Market, By End User

  • 9.1 Introduction
  • 9.2 Hospital & clinics
  • 9.3 Homecare settings
  • 9.4 Ambulatory Care Settings
  • 9.5 Other End Users

10 Global Autoinjectors Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Pfizer, Inc
  • 12.2 Eli Lilly and Company
  • 12.3 AbbVie Inc
  • 12.4 GlaxoSmithKline plc
  • 12.5 Mylan N.V.
  • 12.6 Johnson & Johnson
  • 12.7 Sanofi
  • 12.8 Amgen Inc
  • 12.9 Merck KGaA
  • 12.10 Antares Pharma, Inc.
  • 12.11 Becton, Dickinson, and Company
  • 12.12 Janssen Global Services, LLC
  • 12.13 Teva Pharmaceutical
  • 12.14 Novartis AG
  • 12.15 Bayer AG
  • 12.16 SHL Medical
  • 12.17 Solteam Medical
  • 12.18 Stevanato Group
  • 12.19 Boehringer Ingelheim International GmbH

List of Tables

  • Table 1 Global Autoinjectors Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Autoinjectors Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Autoinjectors Market Outlook, By Reusable (2021-2030) ($MN)
  • Table 4 Global Autoinjectors Market Outlook, By Disposable (2021-2030) ($MN)
  • Table 5 Global Autoinjectors Market Outlook, By Customized (2021-2030) ($MN)
  • Table 6 Global Autoinjectors Market Outlook, By Prefilled (2021-2030) ($MN)
  • Table 7 Global Autoinjectors Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 8 Global Autoinjectors Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 9 Global Autoinjectors Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 10 Global Autoinjectors Market Outlook, By Asthma (2021-2030) ($MN)
  • Table 11 Global Autoinjectors Market Outlook, By Rheumatoid arthritis (2021-2030) ($MN)
  • Table 12 Global Autoinjectors Market Outlook, By Multiple sclerosis (2021-2030) ($MN)
  • Table 13 Global Autoinjectors Market Outlook, By Anaphylaxis (2021-2030) ($MN)
  • Table 14 Global Autoinjectors Market Outlook, By Hormone therapy (2021-2030) ($MN)
  • Table 15 Global Autoinjectors Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 16 Global Autoinjectors Market Outlook, By Migraine (2021-2030) ($MN)
  • Table 17 Global Autoinjectors Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 18 Global Autoinjectors Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 19 Global Autoinjectors Market Outlook, By Intramuscular (2021-2030) ($MN)
  • Table 20 Global Autoinjectors Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 21 Global Autoinjectors Market Outlook, By Technology (2021-2030) ($MN)
  • Table 22 Global Autoinjectors Market Outlook, By Manual (2021-2030) ($MN)
  • Table 23 Global Autoinjectors Market Outlook, By Spring-Loaded (2021-2030) ($MN)
  • Table 24 Global Autoinjectors Market Outlook, By Battery-Powered (2021-2030) ($MN)
  • Table 25 Global Autoinjectors Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 26 Global Autoinjectors Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Autoinjectors Market Outlook, By Hospital & clinics (2021-2030) ($MN)
  • Table 28 Global Autoinjectors Market Outlook, By Homecare settings (2021-2030) ($MN)
  • Table 29 Global Autoinjectors Market Outlook, By Ambulatory Care Settings (2021-2030) ($MN)
  • Table 30 Global Autoinjectors Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.